NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.

The Company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including Lynovex (in oral and inhaled form), an orphan drug candidate for cystic fibrosis (CF), Novexatin, a potential step change therapy for onychomycosis (being co-developed with and out-licensed to Taro Pharmaceuticals) and Novamycin, a novel antifungal peptide in development for the treatment of aspergillosis, candidiasis and cryptococcosis. Novexatin and Novamycin are among the first in class peptide anti-infectives which the company continues to derive from its proprietary antimicrobial peptide rational drug design platform.